Sartobind® Rapid A As An Efficient, Cost-Effective Alternative To Traditional Protein A Resin Chromatography For Smaller-Scale mAb Production

By Raquel Fortuna, Buwadas R. Raut, Zhikang Chen, Yudhi Li, Nguyễn Thị Thuỳ Trang, Đinh Văn Long, Trương Công Thảo, and Y Lim Niê

This compelling application note on the Sartobind® Rapid A membrane chromatography heralds it as a superior alternative to traditional Protein A resin chromatography for monoclonal antibody (mAb) purification. Traditional methods are often plagued by high costs and inefficiencies, primarily due to slow flow rates and extensive setup times. In contrast, Sartobind® Rapid A membranes streamline the capture process, significantly reducing both time and costs while enhancing productivity.

The document is divided into two key sections: the first details a comparative study by Nanogen, showcasing the superior efficiency and impurity removal capabilities of Sartobind® Rapid A over conventional resin-based techniques. The second section provides a thorough financial analysis, emphasizing the economic advantages of transitioning to this innovative platform. Notably, Sartobind® Rapid A membranes demonstrate comparable binding capacity to Protein A resins, achieving remarkable productivity rates—up to 200 g/L/hour—far exceeding that of traditional options. Nanogen's practical application of Sartobind® Rapid A in purifying mAbs like Trastuzumab and Bevacizumab further illustrates its effectiveness, maintaining consistent impurity removal across multiple cycles.

With significant cost savings and enhanced flexibility for multi-product facilities, Sartobind® Rapid A positions itself as a transformative solution in the biopharmaceutical landscape. Access the full application note to learn more.